News >

Treatments Emerging for ROS1-, BRAF-Driven Lung Cancers

Brandon Scalea
Published: Wednesday, Nov 28, 2018

Deepa S. Subramaniam, MBBS, MSc

Deepa S. Subramaniam, MBBS, MSc

Next-generation sequencing (NGS) should be used for all patients with newly diagnosed lung cancer to identify the most personalized treatment approaches, some of which are becoming available for patients with ROS1-positive disease, said Deepa S. Subramaniam, MBBS, MSc.

In ROS1-positive non–small cell lung cancer (NSCLC), crizotinib (Xalkori) is the only FDA-approved drug; however, others have shown promise in recent clinical trials.

For example, in the ongoing, phase I/II TRIDENT-1 study, repotrectinib (TPX-0005) demonstrated a clinically meaningful and durable benefit across multiple doses in patients with ROS1-positive NSCLC. Overall response rates (ORRs) were 80% (95% CI, 44%-97%) for TKI-naïve patients and 18% (95% CI, 4%-44%) for TKI-refractory patients, including 33% for those who received a dose of 160 mg once daily. A range of solid tumors were treated, with the most common being NSCLC (83%).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication